psych1001a-psychdelics

Q: What are psychedelics?

A class of mind-altering drugs that induce altered perception and thought; a subclass of hallucinogens; includes substances that act as agonists or partial agonists on brain serotonin 5-HT2A receptors (e.g., LSD, mescaline, shrooms).

Q: Give examples of common psychedelics.

LSD, mescaline, psilocybin (\"shrooms\").

Q: How were plant-based psychedelics historically used?

Culturally for religious ceremonies, rituals, recreational use; medicinally to treat psychological disorders and physical ailments; for example, cannabis residue found in ancient burials; used as an anesthetic.

Q: Who discovered LSD and when?

Albert Hofmann discovered lysergic acid diethylamide (LSD) in 1943.

Q: What happened during the chemical age of psychedelics?

Empirical research and experimentation began; psychedelics entered psychiatry (1940s–50s); LSD banned in 1966 due to social prejudice; globally banned in 1971 (UN convention); War on Drugs in the 70s; research stopped for 25+ years but recreational use continued.

Q: When did empirical research on psychedelics resume?

In the early 1990s; Rick Strassman’s human studies on DMT safety (1990–95); major research institutions resumed studying psychedelics; by 2010 research expanded to PTSD, anxiety, depression, substance use.

Q: What evidence exists for psychedelics treating depression?

Ayahuasca can act as a rapid antidepressant after one use with no serious side effects; low doses of psilocybin show benefits but need more trials; psilocybin improved mood in eating disorder patients and postpartum depression; the 5-HT2A receptor may explain effects.

Q: What is the ongoing study about psilocybin and risperidone?

A randomized controlled trial is testing combining psilocybin with risperidone (an antipsychotic) for adults with major depressive disorder and treatment-resistant depression; aims to see if risperidone affects psilocybin’s antidepressant effects.

Q: What are the key takeaways on psychedelics for depression?

Research shows strong benefits for treating depression; safe practices and correct dosing are crucial; should always be used under supervision; main harm comes from misuse; more clinical trials are needed.